Terms: = Endocrine gland cancer AND RAF1, Raf-1, 5894, P04049, ENSG00000132155, c-Raf, CRAF AND Treatment
61 results:
1. Decabromodiphenyl ether exposure reduces dabrafenib sensitivity of papillary thyroid carcinoma harboring BRAF
Wang X; Cui X; Wang Y; Wang Q; Sun F; Liu Z
Toxicology; 2024 May; 504():153807. PubMed ID: 38641160
[TBL] [Abstract] [Full Text] [Related]
2. Disruption of the pro-oncogenic c-raf-PDE8A complex represents a differentiated approach to treating KRAS-c-raf dependent PDAC.
Cooke SF; Wright TA; Sin YY; Ling J; Kyurkchieva E; Phanthaphol N; Mcskimming T; Herbert K; Rebus S; Biankin AV; Chang DK; Baillie GS; Blair CM
Sci Rep; 2024 Apr; 14(1):8998. PubMed ID: 38637546
[TBL] [Abstract] [Full Text] [Related]
3. Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic cancer Patient-derived Tumors.
Kazi A; Ranjan A; Kumar M V V; Agianian B; Garcia Chavez M; Vudatha V; Wang R; Vangipurapu R; Chen L; Kennedy P; Subramanian K; Quirke JCK; Beato F; Underwood PW; Fleming JB; Trevino J; Hergenrother PJ; Gavathiotis E; Sebti SM
Cancer Res Commun; 2023 Dec; 3(12):2623-2639. PubMed ID: 38051103
[TBL] [Abstract] [Full Text] [Related]
4. Targeting protein methylation in pancreatic cancer cells results in KRAS signaling imbalance and inhibition of autophagy.
Montenegro MF; Martí-Díaz R; Navarro A; Tolivia J; Sánchez-Del-Campo L; Cabezas-Herrera J; Rodríguez-López JN
Cell Death Dis; 2023 Nov; 14(11):761. PubMed ID: 37996408
[TBL] [Abstract] [Full Text] [Related]
5. Case report: Complete response of an anaplastic thyroid carcinoma patient with
Gui L; Zhu Y; Li X; He X; Ma T; Cai Y; Liu S
Front Immunol; 2023; 14():1178682. PubMed ID: 37122752
[TBL] [Abstract] [Full Text] [Related]
6. Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature.
Lee CL; Holter S; Borgida A; Dodd A; Ramotar S; Grant R; Wasson K; Elimova E; Jang RW; Moore M; Kim TK; Khalili K; Moulton CA; Gallinger S; O'Kane GM; Knox JJ
World J Gastroenterol; 2022 Dec; 28(45):6421-6432. PubMed ID: 36533108
[TBL] [Abstract] [Full Text] [Related]
7. RREB1 promotes the development of parafollicular carcinogenesis through the Ras-raf-1-ELK3 signaling pathway.
Ma S; Wang H; Li W; Yan Z; Luo X; Lu P
Nucleosides Nucleotides Nucleic Acids; 2022; 41(10):972-981. PubMed ID: 35737446
[TBL] [Abstract] [Full Text] [Related]
8. DFMO Improves Survival and Increases Immune Cell Infiltration in Association with MYC Downregulation in the Pancreatic Tumor Microenvironment.
Nakkina SP; Gitto SB; Beardsley JM; Pandey V; Rohr MW; Parikh JG; Phanstiel O; Altomare DA
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947972
[TBL] [Abstract] [Full Text] [Related]
9. The Association of the BRAF-V600E Mutation with the Expression of the Molecular Markers in the Primary Tumor and Metastatic Tissue in Papillary Thyroid cancer.
Spirina LV; Chizhevskaya SY; Kovaleva IV; Kondakova IV
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2017-2024. PubMed ID: 34319022
[TBL] [Abstract] [Full Text] [Related]
10. LncRNA CERS6-AS1 promotes proliferation and metastasis through the upregulation of YWHAG and activation of ERK signaling in pancreatic cancer.
Xu J; Wang J; He Z; Chen P; Jiang X; Chen Y; Liu X; Jiang J
Cell Death Dis; 2021 Jun; 12(7):648. PubMed ID: 34168120
[TBL] [Abstract] [Full Text] [Related]
11. KRAS K104 modification affects the KRAS
Chen CC; Hsu CY; Lin HY; Zeng HQ; Cheng KH; Wu CW; Tsai EM; Hsieh TH
Sci Rep; 2020 Oct; 10(1):17447. PubMed ID: 33060649
[TBL] [Abstract] [Full Text] [Related]
12. HIF-1α and RKIP: a computational approach for pancreatic cancer therapy.
Srivani G; Behera SK; Dariya B; Chalikonda G; Alam A; Nagaraju GP
Mol Cell Biochem; 2020 Sep; 472(1-2):95-103. PubMed ID: 32562168
[TBL] [Abstract] [Full Text] [Related]
13. FAM83D promotes ovarian cancer progression and its potential application in diagnosis of invasive ovarian cancer.
Zhang Q; Yu S; Lok SIS; Wong AST; Jiao Y; Lee LTO
J Cell Mol Med; 2019 Jul; 23(7):4569-4581. PubMed ID: 31037837
[TBL] [Abstract] [Full Text] [Related]
14. Dihydrosanguinarine suppresses pancreatic cancer cells via regulation of mut-p53/WT-p53 and the Ras/Raf/Mek/Erk pathway.
Wu SZ; Xu HC; Wu XL; Liu P; Shi YC; Pang P; Deng L; Zhou GX; Chen XY
Phytomedicine; 2019 Jun; 59():152895. PubMed ID: 30913453
[TBL] [Abstract] [Full Text] [Related]
15. A novel tricarbonylmethane agent (CMC2.24) reduces human pancreatic tumor growth in mice by targeting Ras.
Mallangada NA; Vargas JM; Thomas S; DiGiovanni MG; Vaeth BM; Nemesure MD; Wang R; LaComb JF; Williams JL; Golub LM; Johnson F; Mackenzie GG
Mol Carcinog; 2018 Sep; 57(9):1130-1143. PubMed ID: 29683208
[TBL] [Abstract] [Full Text] [Related]
16. Screening for Thyroid cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Lin JS; Bowles EJA; Williams SB; Morrison CC
JAMA; 2017 May; 317(18):1888-1903. PubMed ID: 28492904
[TBL] [Abstract] [Full Text] [Related]
17. Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid cancer.
Wei WJ; Sun ZK; Shen CT; Song HJ; Zhang XY; Qiu ZL; Luo QY
Theranostics; 2017; 7(4):987-1001. PubMed ID: 28382170
[TBL] [Abstract] [Full Text] [Related]
18. The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid cancer.
Beadnell TC; Mishall KM; Zhou Q; Riffert SM; Wuensch KE; Kessler BE; Corpuz ML; Jing X; Kim J; Wang G; Tan AC; Schweppe RE
Mol Cancer Ther; 2016 Aug; 15(8):1952-63. PubMed ID: 27222538
[TBL] [Abstract] [Full Text] [Related]
19. Selective use of sorafenib in the treatment of thyroid cancer.
Pitoia F; Jerkovich F
Drug Des Devel Ther; 2016; 10():1119-31. PubMed ID: 27042004
[TBL] [Abstract] [Full Text] [Related]
20. Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells.
Hanly EK; Tuli NY; Bednarczyk RB; Suriano R; Geliebter J; Moscatello AL; Darzynkiewicz Z; Tiwari RK
Oncotarget; 2016 Feb; 7(8):8676-87. PubMed ID: 26735176
[TBL] [Abstract] [Full Text] [Related]
[Next]
